Abstracts Archive - Page 418 of 1683 - ATC Abstracts

2020 American Transplant Congress
Minor Negative Effects of Calcineurin Inhibitor Based Immunosuppression on Pregnancy Outcomes after Renal Transplantation in the Netherlands
L. M. Koenjer¹, J. R. Meinderts², A. T. Lely³, M. F. de Jong², O. W. van der Heijden¹, R. G. van der Molen⁴, H. W. van Hamersvelt⁵
¹Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Nephrology, University Medical Center Groningen, Groningen, Netherlands, ³Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Immunology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁵Nephrology, Radboud University Medical Centre, Nijmegen, Netherlands
*Purpose: Pregnancies after renal transplantation became more frequent over the past years, also in patients with compromised renal function. Immunosuppression may influence pregnancy outcome. It…
2020 American Transplant Congress
Impact of a Pharmacist Led Outpatient Tacrolimus Monitoring Protocol in Renal Transplant Recipients
K. L. Owen, M. Palettas, H. Winters, T. E. Pesavento, A. Rajab, O. Witkowsky
Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: The purpose of this study is to compare the time within therapeutic range (TTR) of tacrolimus (TAC) before and after the initiation of a…
2020 American Transplant Congress
De Novo Dosing and Trough Attainment Trends of Extended-Release Tacrolimus in the Absence of Dose Adjustments
M. J. Moritz¹, D. R. Stevens², U. Meier-Kriesche², T. A. Horwedel²
¹Department of Surgery, Lehigh Valley Health Network, Allentown, PA, ²Veloxis Pharmaceuticals, Cary, NC
*Purpose: Initial dosing of tacrolimus extended-release tablets (LCPT) was 0.17 mg/kg/day in the pivotal trial in de novo kidney transplant recipients. Dosing subsequent to the…
2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
B. Shin, N. Ammerman, A. Vo, S. C. Jordan, M. Toyoda, S. Sethi
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…
2020 American Transplant Congress
Pre- And Post-Transplant (Tx) Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody) Treatment Increased Regulatory T Cell (Treg) Percentage in CD4+ T Cells in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts)
S. Ge¹, M. Chu¹, E. D. Ortiz¹, A. D. Guzman¹, A. Vo², N. Ammerman², S. C. Jordan², M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: IL-6 is a B cell growth factor and pro-inflammatory cytokine. Inhibition of IL-6 signaling modulates B cell activation and inflammatory process possibly through Treg…
2020 American Transplant Congress
Liver Transplantation from Donors after Circulatory Death Using “tPA”Protocol: The University of Miami Experience
R. Vianna, A. Farag, G. Selvaggi, A. Tekin, W. De Faria, M. Morsi, R. Miyashiro, T. Beduschi
University of Miami, Miami Transplant Institute, Miami, FL
*Purpose: Expansion of liver transplantation (LT) from donors after circulatory death (DCD) has been increasingly used to overcome the persistent organ shortage and long waiting…
2020 American Transplant Congress
Impact of Concentrations on Conversion from Twice‑Daily to Once‑Daily Tacrolimus in Stable Kidney Graft Recipients: A Single-Center Retrospective Study
Z. Wang, Y. Cao, Y. Fu
Transplant Surgery, Tianjin First Central Hospital, Tian Jin, China
*Purpose: Potential benefits of once-daily tacrolimus include improved adherence to immunosuppressives and decreased Intrapatient variability (IPV) post kidney transplantation. A retrospective analysis was performed to…
2020 American Transplant Congress
A Single-Center Experience in Transfusion-Free Liver Transplantation: Referrals and Outcomes from 2005 to 2019
B. H. Horwich¹, A. Mulgaonkar¹, B. Kim², N. Kaur¹, J. Kahn², Y. Genyk³, A. Ahearn³, H. Han²
¹Internal Medicine, University of Southern California, Los Angeles, CA, ²GI & Liver Diseases, University of Southern California, Los Angeles, CA, ³Surgery, University of Southern California, Los Angeles, CA
*Purpose: The Jehovah’s Witnesses is a religious group known to the medical community for its non-acceptance of blood products. This poses a significant challenge in…
2020 American Transplant Congress
Lowering Meld, Diminishing Length of Stay, and Increasing Liver Transplant Numbers Comes Through the Generosity of Others: Declined HCV-NAT Offers Subsequently Transplanted Have Excellent Outcomes
R. Gilroy, S. Sell, J. Krong, A. Gagnon, I. Zendejas, S. Fujita, M. Rodriguez, D. Alonso
Transplant Services, Intermountain Healthcare, Murray, UT
*Purpose: There is variability between programs in the acceptance of organ offers. This paper examines offer, acceptance and program performance with HCV NAT positive donor…
2020 American Transplant Congress
The Application of Electron Microscope Examination in Evaluation of Donor Liver Quality in Liver Transplantation
M. Chen¹, X. Lin², Z. Chen¹, M. Han¹, W. Ju¹, X. He¹
¹Transplant Center, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²Division of General Surgery, The East Hospital of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: Liver transplantation (LT) is considered as the only curable treatment for patients with end stage liver diseases. Post-operative complications include early allograft dysfunction (EAD),…